

Kazuto Nishio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6355337/publications.pdf>

Version: 2024-02-01

86
papers

3,118
citations

185998

28
h-index

168136

53
g-index

89
all docs

89
docs citations

89
times ranked

5368
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. <i>Science Translational Medicine</i> , 2011, 3, 99ra86.	5.8	543
2	LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. <i>Journal of Clinical Oncology</i> , 2013, 31, 3335-3341.	0.8	303
3	Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474. <i>Cancer Research</i> , 2004, 64, 9101-9104.	0.4	112
4	Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1640-1644.	0.5	107
5	Randomized phase II clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. <i>Cancer Science</i> , 2015, 106, 883-890.	1.7	78
6	SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. <i>International Journal of Cancer</i> , 2009, 124, 1072-1080.	2.3	76
7	Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. <i>Cancer Letters</i> , 2015, 356, 819-827.	3.2	75
8	Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. <i>Scientific Reports</i> , 2016, 6, 36458.	1.6	75
9	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. <i>Oncotarget</i> , 2015, 6, 30850-30858.	0.8	72
10	Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. <i>Scientific Reports</i> , 2015, 5, 14447.	1.6	71
11	Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR). <i>TJ ETQq1 1 0.784314 rgs /Overlo</i>	0.8	70
12	An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. <i>Oncogene</i> , 2019, 38, 1398-1409.	2.6	69
13	HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. <i>Oncotarget</i> , 2016, 7, 3453-3460.	0.8	64
14	Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer: WJOG 6210G. <i>Cancer Science</i> , 2016, 107, 1843-1850.	1.7	60
15	Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. <i>International Journal of Cancer</i> , 1995, 63, 688-693.	2.3	54
16	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition). <i>TJ ETQq0 0 0.18 rgs /Overlock 10 TF</i>	1.8	49
17	Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 329-333.	0.9	45
18	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388.	3.9	43

#	ARTICLE	IF	CITATIONS
19	Dimerization and the signal transduction pathway of a smallin-frame deletion in the epidermal growth factor receptor. <i>FASEB Journal</i> , 2006, 20, 311-313.	0.2	41
20	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. <i>Lung Cancer</i> , 2016, 91, 36-40.	0.9	38
21	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1 1,0,784314,rgBT/O	1.7	38
22	Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. <i>British Journal of Cancer</i> , 2021, 124, 914-924.	2.9	37
23	Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. <i>Lung Cancer</i> , 2019, 127, 59-65.	0.9	36
24	A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). <i>Clinical Cancer Research</i> , 2022, 28, 893-902.	3.2	35
25	A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. <i>Breast</i> , 2018, 40, 67-75.	0.9	34
26	HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 390-403.	3.2	34
27	MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. <i>Lung Cancer</i> , 2015, 90, 590-597.	0.9	32
28	Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. <i>Molecular Cancer</i> , 2014, 13, 126.	7.9	31
29	Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. <i>Cancer Science</i> , 2016, 107, 1660-1666.	1.7	31
30	FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. <i>Cancer Science</i> , 2016, 107, 1667-1676.	1.7	31
31	Mutational activation of the epidermal growth factor receptor downregulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 52-60.	1.7	31
32	Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2015, 10, e0121891.	1.1	30
33	Multiplex gene-panel testing for lung cancer patients. <i>Pathology International</i> , 2020, 70, 921-931.	0.6	29
34	Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. <i>Gynecologic Oncology</i> , 2020, 156, 415-422.	0.6	28
35	Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. <i>Cancer Science</i> , 2018, 109, 3921-3933.	1.7	27
36	Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using Cancer Personalized Profiling by deep Sequencing. <i>Scientific Reports</i> , 2019, 9, 10426.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. <i>JCI Insight</i> , 2019, 4, .	2.3	26
38	The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. <i>Oncotarget</i> , 2017, 8, 70736-70751.	0.8	26
39	Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells. <i>PLoS ONE</i> , 2014, 9, e104372.	1.1	25
40	Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a <i>PTEN</i> -deficient mouse model of prostate cancer. <i>Carcinogenesis</i> , 2014, 35, 2142-2153.	1.3	23
41	Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors. <i>Cancer</i> , 2020, 126, 219-227.	2.0	20
42	Efficacy of targeted AKT inhibition in genetically engineered mouse models of <i>PTEN</i> -deficient prostate cancer. <i>Oncotarget</i> , 2016, 7, 15959-15976.	0.8	20
43	Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin. <i>PLoS ONE</i> , 2014, 9, e94772.	1.1	19
44	Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. <i>Oncotarget</i> , 2015, 6, 21636-21644.	0.8	19
45	Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. <i>Lung Cancer</i> , 2019, 132, 59-64.	0.9	18
46	Plasma screening for the T790M mutation of <i>EGFR</i> and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. <i>Cancer</i> , 2020, 126, 1940-1948.	2.0	18
47	Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. <i>Cancer Letters</i> , 2017, 405, 22-28.	3.2	17
48	Guidelines for clinical evaluation of anti-cancer drugs. <i>Cancer Science</i> , 2021, 112, 2563-2577.	1.7	17
49	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. <i>Molecular Oncology</i> , 2022, 16, 1493-1507.	2.1	17
50	Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. <i>Cancer Science</i> , 2021, 112, 3911-3917.	1.7	17
51	MEK Inhibitor for Gastric Cancer with <i>MEK1</i> Gene Mutations. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3098-3106.	1.9	16
52	Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas. <i>Cancer</i> , 2015, 121, 4359-4368.	2.0	16
53	Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. <i>Oncologist</i> , 2019, 24, 1022-1026.	1.9	16
54	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). <i>Cancer Science</i> , 2021, 112, 388-396.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. <i>International Journal of Oncology</i> , 2017, 50, 2049-2058.	1.4	15
56	Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV-1 strains. <i>Cancer Science</i> , 2021, 112, 1300-1309.	1.7	14
57	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <i>Clinical Lung Cancer</i> , 2017, 18, 719-723.	1.1	13
58	Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU. <i>Cancer Science</i> , 2008, 99, 1859-1864.	1.7	12
59	Predicting osimertinib treatment outcomes through EGFR mutant fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). <i>Molecular Oncology</i> , 2021, 15, 126-137.	2.1	12
60	Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens. <i>Cancer Science</i> , 2019, 110, 2044-2049.	1.7	11
61	Predictive value of EGFR mutation in non-small cell lung cancer patients treated with platinum doublet postoperative chemotherapy. <i>Cancer Science</i> , 2022, 113, 287-296.	1.7	10
62	Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. <i>Frontiers in Oncology</i> , 2021, 11, 763468.	1.3	10
63	Successful Long-Term Treatment With Pemetrexed of NSCLC Associated With EML4-ALK and Low Thymidylate Synthase Expression. <i>Clinical Lung Cancer</i> , 2012, 13, 157-159.	1.1	9
64	Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. <i>SpringerPlus</i> , 2015, 4, 7.	1.2	9
65	Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. <i>Cancer Science</i> , 2019, 110, 3350-3357.	1.7	8
66	Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. <i>Scientific Reports</i> , 2020, 10, 691.	1.6	8
67	Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model. <i>Cancers</i> , 2021, 13, 3683.	1.7	7
68	Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 1827-1831.	0.5	7
69	Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 161, 44-54.	1.3	7
70	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. <i>Lung Cancer</i> , 2020, 148, 100-104.	0.9	6
71	Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. <i>Oncology Letters</i> , 2015, 9, 405-410.	0.8	5
72	Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. <i>Lung Cancer</i> , 2020, 139, 28-34.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-“Small Cell Lung Cancers: Analysis of Five Cases. <i>Clinical Lung Cancer</i> , 2021, 22, e141-e145.	1.1	5
74	A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9037-9037.	0.8	5
75	Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 2071-2079.	2.9	5
76	High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100191.	0.6	5
77	Decreased expression of T-Cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma. <i>Cancer Science</i> , 2021, , .	1.7	5
78	ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells. <i>Cells</i> , 2022, 11, 702.	1.8	5
79	Performance of Idylla- [®] RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1180-1187.	1.0	5
80	Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer. <i>Cancers</i> , 2021, 13, 3975.	1.7	4
81	METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 361-370.	0.0	3
82	Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy. <i>Esophagus</i> , 2021, 18, 306-314.	1.0	2
83	Successful long-term treatment of non-“small cell lung cancer positive for RET rearrangement with pemetrexed. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5355-5358.	1.0	1
84	Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis. <i>Journal of Dermatological Science</i> , 2020, 100, 217-219.	1.0	1
85	Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period. <i>Hepatology International</i> , 2022, 16, 135-147.	1.9	1
86	RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100303.	0.6	1